Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis

BACKGROUND: Accumulating data shows that exon 19 deletions and L858R, both activating epidermal growth factor receptor mutations in non-small-cell lung cancers (NSCLCs), are just two different entities in terms of prognosis and treatment response to tyrosine kinase inhibitors (TKIs). METHODS: A syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuan, Feng-Che, Kuo, Liang-Tseng, Chen, Min-Chi, Yang, Cheng-Ta, Shi, Chung-Sheng, Teng, David, Lee, Kuan-Der
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Genetics & Genomics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815883/
https://www.ncbi.nlm.nih.gov/pubmed/26461059
http://dx.doi.org/10.1038/bjc.2015.356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815883/
https://www.ncbi.nlm.nih.gov/pubmed/26461059
http://dx.doi.org/10.1038/bjc.2015.356

Ejemplares similares